Currently, cancer patients who experience recurrence of disease face a challenging prognosis and limited new treatment options – especially in glioblastoma (brain cancer), colorectal, pancreatic, ovarian, and small cell lung cancers.
High toxicity levels in available marketed treatments can lead to their discontinuation, due to tolerability and/or quality of life issues.
Vivacitas’ lead program AR-67, is a lipophilic small molecule compound with a proprietary synthesis method developed to address especially hard-to-treat tumors and improve tolerability and patient comfort.
Novel technology
Using breakthrough technology to evolve current treatments and improve patient quality of life.
Advancing current treatment
AR-67 is a new generation of treatment, building on its current strengths and advancing it further.
Proprietary method
Our patented synthesis method has the potential to transform the current oncology treatment space.
Powerful technical expertise
Our expert team brings a scientific pedigree of vision and tenacity to push innovation forward.
Backed by clinical data
Preclinical, Phase I, and Phase II clinical data for AR-67 already shows promise for treatment of tough-to-treat cancers such as recurrent glioblastoma.
Patient-centric Focus
The patient is at the heart of everything we do and fuels our ambitions to accelerate innovation for scientific discovery.
Preclinical, Phase 1 & Phase II Trials Indicate:
- Progression-Free Survival of 6 months or more
- Overall Survival of 6 months or more
- Safety/Toxicity superior to existing Camptothecins
- Tolerability superior to Lomustine